No Data
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
Express News | Jasper Therapeutics: Data From Newly Added 360Mg Single-Dose Cohort Is Expected to Be Reported in H1 2025
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $80